These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23039216)

  • 21. Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study.
    Kuroda N; Kusunoki Y; Osugi K; Ohigashi M; Azuma D; Ikeda H; Makino S; Otsuka A; Tamada D; Watanabe N; Washio K; Tsunoda T; Matsuo T; Konishi K; Katsuno T; Koyama H;
    J Diabetes Investig; 2021 Feb; 12(2):244-253. PubMed ID: 32594655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Individualised treatment targets in patients with type-2 diabetes and hypertension.
    Schmieder RE; Tschöpe D; Koch C; Ouarrak T; Gitt AK;
    Cardiovasc Diabetol; 2018 Jan; 17(1):18. PubMed ID: 29357854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
    Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
    Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensive Glycemic Control in Type 2 Diabetes Mellitus -- A Balancing Act of Latent Benefit and Avoidable Harm: A Teachable Moment.
    Rodriguez-Gutierrez R; Lipska KJ; McCoy RG
    JAMA Intern Med; 2016 Mar; 176(3):300-1. PubMed ID: 26882223
    [No Abstract]   [Full Text] [Related]  

  • 27. Risk of severe hypoglycemia in sulfonylurea-treated patients from diabetes centers in Germany/Austria: How big is the problem? Which patients are at risk?
    Schloot NC; Haupt A; Schütt M; Badenhoop K; Laimer M; Nicolay C; Reaney M; Fink K; Holl RW
    Diabetes Metab Res Rev; 2016 Mar; 32(3):316-24. PubMed ID: 26409039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis.
    Lee P; Chang A; Blaum C; Vlajnic A; Gao L; Halter J
    J Am Geriatr Soc; 2012 Jan; 60(1):51-9. PubMed ID: 22239291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Oral antidiabetic agents and hypoglycemia in elderly patients].
    Porzi J; Petriccioli N; Malacarne S
    Rev Med Suisse; 2020 Feb; 16(680):264-267. PubMed ID: 32022491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
    Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
    JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between measures of hypoglycemia and glycemic improvement in sulfonylurea treated patients with type 2 diabetes in India: results from the OBSTACLE hypoglycemia study.
    Kalra S; Deepak MC; Narang P; Singh V; Maheshwari A
    J Postgrad Med; 2014; 60(2):151-5. PubMed ID: 24823514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between glycated hemoglobin level and duration of hypoglycemia in type 2 diabetes patients treated with sulfonylureas: A multicenter cross-sectional study.
    Matsuoka A; Hirota Y; Takeda A; Kishi M; Hashimoto N; Ohara T; Higo S; Yamada H; Nakamura T; Hamaguchi T; Takeuchi T; Nakagawa Y; Okada Y; Sakaguchi K; Ogawa W
    J Diabetes Investig; 2020 Mar; 11(2):417-425. PubMed ID: 31461223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CYP2C19 Loss-of-function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 Diabetes.
    Wang K; Yang A; Shi M; Tam CCH; Lau ESH; Fan B; Lim CKP; Lee HM; Kong APS; Luk AOY; Tomlinson B; Ma RCW; Chan JCN; Chow E
    Clin Pharmacol Ther; 2022 Feb; 111(2):461-469. PubMed ID: 34656068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidiabetic pharmacotherapy and anamnestic hypoglycemia in a large cohort of type 2 diabetic patients--an analysis of the DiaRegis registry.
    Tschöpe D; Bramlage P; Binz C; Krekler M; Plate T; Deeg E; Gitt AK
    Cardiovasc Diabetol; 2011 Jul; 10():66. PubMed ID: 21756359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative studies of dipeptidyl peptidase 4 inhibitor vs sulphonylurea among Muslim Type 2 diabetes patients who fast in the month of Ramadan: A systematic review and meta-analysis.
    Loh HH; Yee A; Loh HS; Sukor N; Kamaruddin NA
    Prim Care Diabetes; 2016 Jun; 10(3):210-9. PubMed ID: 26392074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration.
    Laires PA; Tang J; Fan CP; Li Z; Qiu Y; Iglay K
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):213-220. PubMed ID: 27345181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of health policy and practice on finding the best fit for patients with type 2 diabetes after metformin failure: Croatian pilot study.
    Cigrovski Berković M; Herman Mahečić D; Gradišer M; Bilić-Ćurčić I
    Prim Care Diabetes; 2017 Jun; 11(3):265-272. PubMed ID: 28314484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comorbidity, hypoglycaemia and appropriate selection of antidiabetic pharmacotherapy in diabetic patients with heart failure in clinical practice in Germany. Results of the DiaRegis registry.
    Gitt AK; Bramlage P; Binz C; Krekler M; Deeg E; Tschöpe D
    Herz; 2012 May; 37(3):294-300. PubMed ID: 22476616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of once-daily insulin detemir in patients with type 2 diabetes treated with oral hypoglycemic agents in routine clinical practice.
    Ross S; Dzida G; Ji Q; Kaiser M; Ligthelm R; Meneghini L; Nazeri A; Orozco-Beltran D; Pan C; Svendsen AL;
    J Diabetes; 2014 May; 6(3):243-50. PubMed ID: 24103141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study.
    Andersen A; Bagger JI; Sørensen SK; Baldassarre MPA; Pedersen-Bjergaard U; Forman JL; Gislason G; Lindhardt TB; Knop FK; Vilsbøll T
    Cardiovasc Diabetol; 2021 Dec; 20(1):241. PubMed ID: 34952579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.